Epigenetics Market Global Industry Size, Segments, Share and Growth Factor Analysis Research Report

The key factors that are driving the growth of Epigenetics Market include the decreasing sequencing costs and time, increase in research activities to identify and develop inhibitors/drugs for various diseases, funding for epigenetics research, and rising prevalence of cancer.

The epigenetics market is projected to reach $1,605.7 million by 2022 from an estimated $854.0 million in 2017, at a CAGR of 13.5% during the forecast period.

According to a press release published by the Tufts Center for the Study of Drug Development in May 2015, biopharmaceutical companies have nearly doubled their R&D investments in personalized medicine over the last five years, and these investments are further expected to increase by 33% over the next five years. This will further drive the use of epigenetics tools.

Among the Application Segments, Oncology Dominated the Global Epigenetics Market in 2016 

Based on application, the oncology segment accounted for the largest share of the Epigenetics Market in 2016. The large share of this segment can be attributed to the rising prevalence of cancer and the increasing number of research-related activities.

Download PDF Brochure: 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=896

North America accounted for the largest share of the Epigenetics Market in 2016, followed by Europe. Increase in epigenetics research activities, favorable government funding initiatives, high R&D expenditure, rising incidence of various diseases, and the presence of key players in the region are the key factors driving the growth of the Epigenetics Market in North America.

The major players in the Global Epigenetics Market are Illumina (US), Thermo Fisher (US), Diagenode (Belgium), QIAGEN (US), Merck Millipore (US), Abcam (UK), Active Motif (US), New England Biolabs (US), Agilent (US), Zymo Research (US), PerkinElmer (US), and Bio-Rad (US).